- Home
- PAMT vs ABEO Comparison
PAMT vs ABEO Comparison
Compare PAMT & ABEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PAMT | ABEO |
|---|---|---|
| Founded | 1980 | 1974 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trucking Freight/Courier Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 268.9M | 320.3M |
| IPO Year | N/A | 2005 |
Fundamental Metrics
Financial Performance| Metric | PAMT | ABEO |
|---|---|---|
| Price | $14.75 | $5.61 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $13.00 | ★ $20.00 |
| AVG Volume (30 Days) | 15.2K | ★ 1.0M |
| Earning Date | 05-12-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 165.16 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,998,000.00 |
| Revenue This Year | $20.12 | $1,024.31 |
| Revenue Next Year | N/A | $145.42 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 258.18 |
| 52 Week Low | $7.15 | $4.00 |
| 52 Week High | $16.50 | $7.54 |
Technical Indicators
Market Signals| Indicator | PAMT | ABEO |
|---|---|---|
| Relative Strength Index (RSI) | 59.21 | 50.96 |
| Support Level | $9.71 | $5.24 |
| Resistance Level | $16.50 | $5.64 |
| Average True Range (ATR) | 1.08 | 0.21 |
| MACD | -0.10 | -0.00 |
| Stochastic Oscillator | 52.97 | 57.81 |
Price Performance
Historical ComparisonAbout PAMT PAMT CORP
PAMT Corp is a holding company that is engaged in providing truckload dry van carriers transporting general commodities throughout the continental United States, as well as the Canadian provinces of Ontario and Quebec. It has one reportable segment being motor carrier.
About ABEO Abeona Therapeutics Inc.
Abeona Therapeutics Inc is a commercial-stage biopharmaceutical company. The company is focused on developing cell and gene therapies for life-threatening diseases. The company's ZEVASKYN (prademagene zamikeracel) is an autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). The company's development portfolio includes adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need.